YTS109
Phase 1Biologic
YTS109 is one of 12 biologic programs targeting Hemolytic Anemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Hemolytic Anemia
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Neoral
NovartisPhase 3
Imbruvica
PPharmacyclics LLC.
Phase 2
Fostamatinib Bid
RRigel Pharmaceuticals
Phase 3
HMPL-523
HHutchison Medipharma Limited
Phase 3
Fabhalta
NovartisPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
YTS109 Cell
CChina Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
Inaticabtagene Autoleucel
JJuventas Cell Therapy Ltd.
Phase 1
Thiscart19a
FFundamenta Therapeutics, Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hemolytic Anemia1 trial
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06770504·7 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YTS109. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details